Added to YB: 2025-11-18
Pitch date: 2025-11-14
CRMD [neutral]
CorMedix Inc.
+1.43%
current return
Author Info
No bio for this author
Company Info
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Market Cap
$885.6M
Pitch Price
$11.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
9.02
P/E
4.99
EV/Sales
4.57
Sector
Pharmaceuticals
Category
value
$CRMD Earnings Update
CRMD (earnings): Q3 shows strong Defencath launch w/ $88.8M revenue, $72M adj EBITDA. LDO uptake ahead of expectations. Trading 3.5x EV/EBITDA on run-rate basis w/ double-digit growth until H2 2026. Melinta acquisition adds diversification, $400M pro forma rev target. Key risk: uncertain pricing post-TDAPA bundle inclusion.
Read full article (2 min)